On April 22, 2025 OncoSpherix, a biotech company pioneering innovative therapies for tumor hypoxia, reported its participation in Portal Innovations’ ‘Rising Stars in Oncology’ event during the 2025 American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting in Chicago (Press release, OncoSpherix, APR 22, 2025, View Source [SID1234652016]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The event, taking place on April 25, 2025, will spotlight emerging biotech companies developing breakthrough cancer treatments. OncoSpherix will present its latest advancements in targeting the hypoxia-inducible factor 1 (HIF-1) pathway, thereby disrupting essential processes that fuel tumor growth, metastasis, and resistance to therapy.

"We are honored to be recognized as a rising innovator in oncology," said OncoSpherix CEO, Margaret Offermann, MD, PhD. "This event provides a unique platform to share our mission and engage with leading investors, researchers, and industry experts."

The ‘Rising Stars in Oncology’ event, hosted by Portal Innovations, brings together cutting-edge biotech companies, venture investors, and scientific leaders to showcase promising advancements in cancer therapeutics.

For more details on the event, visit: View Source